In today’s recent session, 7.69 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) have been traded, and its beta is 2.06. Most recently the company’s share price was $2.11, and it changed around -$0.12 or -5.61% from the last close, which brings the market valuation of the company to $573.32M. PACB at last check was trading at a discount to its 52-week high of $14.55, offering almost -589.57% off that amount. The share price’s 52-week low was $1.25, which indicates that the recent value has risen by an impressive 40.76% since then. We note from Pacific Biosciences of California Inc’s average daily trading volume that its 3-month average coming to 10.97 million.
Pacific Biosciences of California Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.21. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 4 recommended PACB as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Pacific Biosciences of California Inc is expected to report earnings per share of -$0.23 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB has been showing red trend so far today with a performance of -5.61% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -78.54% year-to-date, but still up 25.30% over the last five days. On the other hand, Pacific Biosciences of California Inc (NASDAQ:PACB) is 50.36% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $2.8, which translates to bulls needing to increase their stock price by 24.64% from its current value. Analyst projections state that PACB is forecast to be at a low of $2 and a high of $4.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Pacific Biosciences of California Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -67.31 percent over the past six months and at a 12.61% annual growth rate that is well below the industry average of 14.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 17.90% in revenue this quarter, and will report an increase of 19.20% in the next quarter. The year-over-year growth rate is expected to be -8.00%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of $41.72 million in revenue for the current quarter. 10 analysts expect Pacific Biosciences of California Inc to make $46.48 million in revenue for the quarter ending Sep 2024. The company’s sales for a year ago were $55.69 million respectively. Forecasts for the next quarter put sales growth at -16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.76%. Pacific Biosciences of California Inc earnings are expected to increase by 23.49% in 2024, but the outlook is negative -1.00% per year for the next five years.
